Menlo therapeutics inc. (MNLO)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15
Operating activities
Net loss

-73,703

-51,445

-29,076

-14,068

-4,608

Adjustments required to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

56

22

8

4

-

Amortization of right-of-use-asset

644

-

-

-

-

Depreciation and amortization

56

22

8

4

0

Changes in marketable securities and bank deposits, net

-

-

-

-

0

Amortization of premium on investment securities

691

774

-66

-158

0

Stock-based compensation

6,701

3,638

1,452

573

65

Changes in operating asset and liabilities, net of effects of businesses acquired:
Gain on disposal of equipment

-

-

-19

0

0

Accrued interest

-

-

31

0

0

Change in operating assets and liabilities:
Accounts receivable

-

-786

786

0

0

Prepaid expenses and other current assets

-1,867

-324

1,790

555

-

Prepaid expenses and other current assets

-1,867

-324

1,790

555

22

increase in other non-current assets

-209

282

-66

66

-

Prepaid and other long-term assets

-

-

-

-

0

Accounts payable

481

825

620

889

0

Accrued expenses and other current liabilities

-44

2,719

2,976

466

346

Deferred revenue

-

-8,531

-1,796

10,327

-

Lease liability

-614

-

-

-

-

Deferred revenue

-

-

-

-

36

Other non-current liabilities

-7

-15

-12

7

0

Net cash used in operating activities

-65,101

-52,733

-28,222

-2,265

-4,183

CASH FLOWS FROM INVESTING ACTIVITIES:
Investing activities
Purchase of fixed assets

11

140

27

31

0

Investment in bank deposits

83,397

126,700

64,148

55,309

0

Proceeds from sales of investments

14,042

5,100

6,000

-

-

Proceeds from sales of investments

-

-

-

3,600

0

Proceeds from maturities of investments

110,740

87,864

43,085

14,224

0

Net cash provided by investing activities

41,374

-33,876

-15,090

-37,516

0

CASH FLOWS FROM FINANCING ACTIVITIES:
Financing activities
Issuance of common stock pursuant to public offering, net of issuance costs

-

125,417

-

-

-

Proceeds from issuance of convertible preferred stock, net of issuance costs

-

-

50,324

0

47,620

Proceeds related to issuance of stock for stock-based compensation arrangements, net

36

496

34

0

98

Proceeds from purchases under the Employee Stock Purchase Plan

429

-

-

-

-

Proceeds from issuance of common stock under at-the-market offering

4,529

-

-

-

-

Deferred financing costs

-

-

867

0

0

Net cash provided by financing activities

4,994

125,913

49,491

0

47,718

Net increase (decrease) in cash and cash equivalents

-18,733

39,304

6,179

-

-

Net increase in cash and cash equivalents

-

-

-

-39,781

43,535

Noncash financing activities
Addition of right-of-use-asset

1,314

-

-

-

-

Conversion of preferred stock to common stock

-

109,327

-

-

-

Deferred financing costs

-

-

316

0

0